More articles from Volume 46, Issue 3, 2017
Randomization techniques in protocols for cluster randomized trials
Systematic review of factor validity of psychiatric scales in longitudinal studies
Comparison of clinical, biochemical and morphological parameters in patients with chronic hepatitis B
Impact of ocular comorbidities on visual function and quality of life in cataract and pseudophakic patients
Effects of different doses of zinc gluconate on antioxidative activity of metformin and glibenclamide on experimentally induced diabetes in rabbits
Citations
0
Cognitive functions of patients with epilepsy treated by topiramate
Abstract
Topiramate is a newer drug with a strong antiepileptic potential, but also with adverse effects, especially on cognitive functions. This review deals with the study covering the impact of topiramate on cognition in patients with epilepsy. The most common side effects are included somnolence, psychomotor slowing, difficulty in memory, concentration and attention disorder and problems with speaking. Most studies have shown that a high initial dose, rapid titration and application in polytherapy increase the risk of cognitive impairment after-introduction of topiramate. In addition, depression and early onset of the disease can also contribute to cognitive adverse effects, even at low doses of the drug. Although topiramate indisputably linked to the risk of interference cognitive impairments, some studies suggest their reversibility. This, together with high efficiency antiepileptic obliges researchers to continue searching for the risk factors and mechanisms of cognitive side effects in order to define the profile of patients who would be of maximum benefit of the drug in controlling seizures with absent or acceptable side effects.
Keywords
References
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
